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Abstract: Introduction: Antibody treatment with anti-thymocyte globulin (ATG) has been shown
to be cardioprotective. We aimed to evaluate which single anti-T-cell epitope antibody alters
chemokine expression at a level similar to ATG and identified CD3, which is a T-cell co-receptor
mediating T-cell activation. Based on these results, the effects of anti-CD3 antibody treatment on
angiogenesis and cardioprotection were tested in vitro and in vivo. Methods: Concentrations of
IL-8 and MCP-1 in supernatants of human peripheral blood mononuclear cell (PBMC) cultures
following distinct antibody treatments were evaluated by Enzyme-linked Immunosorbent Assay
(ELISA). In vivo, anti-CD3 antibodies or vehicle were injected intravenously in rats subjected to acute
myocardial infarction (AMI). Chemotaxis and angiogenesis were evaluated using tube and migration
assays. Intracellular pathways were assessed using Western blot. Extracellular vesicles (EVs) were
quantitatively evaluated using fluorescence-activated cell scanning, exoELISA, and nanoparticle
tracking analysis. Also, microRNA profiles were determined by next-generation sequencing. Results:
Only PBMC stimulation with anti-CD3 antibody led to IL-8 and MCP-1 changes in secretion, similar
to ATG. In a rat model of AMI, systemic treatment with an anti-CD3 antibody markedly reduced
infarct scar size (27.8% (Inter-quartile range; IQR 16.2–34.9) vs. 12.6% (IQR 8.3–27.2); p < 0.01). The
secretomes of anti-CD3 treated PBMC neither induced cardioprotective pathways in cardiomyocytes
nor pro-angiogenic mechanisms in human umbilical vein endothelial cell (HUVECs) in vitro. While
EVs quantities remained unchanged, PBMC incubation with an anti-CD3 antibody led to alterations
in EVs miRNA expression. Conclusion: Treatment with an anti-CD3 antibody led to decreased scar
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size in a rat model of AMI. Whereas cardioprotective and pro-angiogenetic pathways were unaltered
by anti-CD3 treatment, qualitative changes in the EVs miRNA expression could be observed, which
might be causal for the observed cardioprotective phenotype. We provide evidence that EVs are
a potential cardioprotective treatment target. Our findings will also provide the basis for a more
detailed analysis of putatively relevant miRNA candidates.
Keywords: myocardial infarction; CD3; anti-CD; antibody treatment; cardioprotection; AMI;
apoptosis; angiogenesis; miRNA
1. Introduction
In spite of advances in reperfusion therapy, ischemic cardiomyopathy after acute myocardial
infarction (AMI) still causes high morbidity [1]. Medical management of heart failure due to reduced
ejection fraction has dramatically improved outcomes, but the great hope put in stem cell therapy
to improve cardiac output has been dampened by inconsistent results from randomized clinical
trials [2–6].
Anti-thymocyte globulin (ATG) has been shown to have cardioprotective, pro-angiogenic, and
chemotactic effects in a rat model of acute myocardial infarction (AMI) [7]. ATG was formerly used in
transplantation medicine and is known to induce apoptosis in T-cells, depletion of T-cell depletion and
T-cell activation, depletion of antigen-presenting cells, and to induce regulatory T-cells and natural
killer T cells [8,9]. ATG administration induces “paracrine effects” in cardiomyocytes in AMI [7]. The
“paracrine paradigm” was developed after inconsistent results in large “stem cell therapy” trials [10,11].
Recently, Vagnozzi et al. underscored the merit of this concept and showed that cardiac “stem cell
therapy” induces a wound healing and inflammatory cascade [12]. The results of our research and
research by others have shown that not only secretomes of bone marrow-derived stem cells (BMCs)
but also of peripheral blood mononuclear cells (PBMC) exert angiogenic and cardioprotective effects
similar to effects seen in “stem cell therapy” [7,13–15].
Several potential mechanisms have been discussed to mediate the cardioprotective, angiogenic,
and cardiac remodeling effects observed in therapeutic approaches using “stem cell” secretomes.
Differential cell culture conditions led to changes in the secretomes of both BMCs and PBMCs, e.g., in
the concentration of interleukin-8 (IL-8) which was shown to induce angiogenesis, to be cardioprotective
and to inhibit hypoxia-induced apoptosis in HUVECs [16]. Cardioprotective signaling pathways
induced by IL-8 were mediated via Akt1 and ERK1/2 [17,18]. Furthermore, IL-8 is known to promote
angiogenesis via endothelial progenitor cell homing [19]. Other chemokines such as Interleukin-6
(IL-6) and tumor necrosis factor-alpha (TNFα) were found to induce angiogenesis as well, besides their
pro-inflammatory effects [20,21].
Besides chemokines and cytokines, extracellular vesicles (EVs) have been identified as mediators
of cardioprotective and angiogenic effects. Newly described key players in exosome-mediated effects
are non-coding RNAs such as microRNA (miRNA), some of which exert profound cardioprotective
effects [22,23].
Thus, paracrine effects induced by T-cell stimulation may represent a promising concept.
Nevertheless, the administration of ATG in AMI is precluded in clinical practice due to known
adverse reactions such as anaphylaxis, thrombocytopenia, hypotension and especially cytokine release
syndrome. On the other hand, in the acute setting of AMI, a ready-to-use antibody might still
be preferable over-complicated stem cell therapies necessitating individual stem cell purification
and preparation.
An anti-CD3 antibody has emerged as an alternative candidate, among other antibodies. Activation
of the CD3 T-cell co-receptor induces activation, proliferation, and alters cytokine production of
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T-cells [24,25]. From a clinical standpoint, an anti-CD3 antibody was recently successfully evaluated in
patients at risk for type-1 diabetes, evidencing clinical safety [26].
Based on these considerations and previous work, we, therefore, aimed to evaluate (1) which
single anti-T-cell-epitope antibody alters chemokine expression at a similar or superior level compared
to ATG, (2) if treatment using this antibody is cardioprotective in an animal model of AMI, (3) if
potential effects are mediated by angiogenesis, chemotaxis and cardio-protection and (4) if antibody
treatment leads to quantitative and/or qualitative alterations in the exosome secretion profile of PBMCs.
2. Materials and Methods
2.1. Cell Culture of Human PBMC
All experimental procedures involving human cells were approved by the local ethics committee
(415-E/1895/4-2015) and were conducted in compliance with the Declaration of Helsinki Principles.
Human peripheral blood mononuclear cells (PBMC) were obtained from young healthy volunteers
after informed written consent. Inclusion criteria were: body mass index 18–40 kg/m2, no autoimmune
disease, no intake of anti-inflammatory drugs during the last month, no sign of acute infection
during the previous month, and no chronic inflammatory disease. PBMC were separated using
the Ficoll-Paque technique (Ficoll® Paque Plus, Sigma Aldrich, Vienna, Austria) density gradient
centrifugation as described previously [16]. Cells were resuspended in X-VIVO™ 10 Chemically
Defined, Serum-free Hematopoietic Cell Medium (Lonza, Switzerland) and cultured in a humidified
atmosphere for 24 h at a density of 1.0 × 106 cells/mL, n = 10). For cell culture experiments, ATG
(Thymoglobulin, Genzyme, Germany) was added at various concentrations from 5 to 250 µg/mL.
Additional dose titration experiments were conducted with increasing concentrations of anti-CD3
antibodies (5 µg, 10 µg and 25 µg).
In experiments to identify the specific T cell epitope that, once co-incubated with 20 µg/mL
antibodies, induced the most pronounced chemokine secretion, the following T-cell epitopes were
screened: CD4, CD8, CD11a, CD3, CD28, CD2, and HLA-DR. ATG (20 µg/mL) served as a positive
control and untreated cells as well as the use of isotype antibodies (IgG1 and IgG2a) served as negative
controls. All antibodies were obtained from BD Biosciences, Heidelberg, Germany.
2.2. Membrane Proteome Analysis
The obtained supernatants were screened for cytokines and angiogenic factors using commercially
available antibody array systems (Human XL Cytokine Array Kit Proteome Profiler Array, Catalog
Number ARY022B, R&D Systems, Minneapolis, USA) according to the manufacturer’s instructions. In
short, capture and control antibodies have been pre-spotted in duplicate on nitrocellulose membranes.
The cell culture supernatants of controls (unstimulated PBMCs, pooled supernatants) or ATG stimulated
cells were added to and incubated overnight with the Proteome Profiler Array membrane on a rocking
platform shaker. After the incubation period, the membrane was washed to remove unbound material
followed by incubation with a cocktail of biotinylated detection antibodies. Streptavidin-HRP and
chemiluminescent detection reagents were then applied, producing a signal at each capture spot
corresponding to the amount of protein-bound. For analysis, membranes were transferred to an
autoradiography film cassette and a Western blot imaging device ChemiDoc XRS imager (Bio-Rad,
Hercules, CA, USA) for a total of nine minutes.
2.3. ELISA Analysis
Levels of selected cytokines secreted into the supernatant by PBMCs co-incubated with ATG
or other antibodies were measured by using commercially available enzyme-linked immunosorbent
assays (ELISA; Duoset, R&D Systems, Minneapolis, MN, USA) kits for the quantification of IL-8, MCP-1
and Angiogenin according to the manufacturer’s protocol. ELISA assays were performed in accordance
with instructions supplied by the manufacturer. In short, cell culture supernatant samples and standard
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proteins were added to the multi-well plate coated with the respective capture antibody and incubated
for two hours. Plates were then washed using washing buffer (Tween 20, and phosphate-buffered
saline solution, Sigma Aldrich, St.Louis, MO, USA). In the next step, a biotin-labeled antibody was
added to each well and incubated for another two hours. ELISA plates were washed again, and a
streptavidin-horseradish-peroxidase solution was added. After adding tetramethylbenzidine (TMB;
Sigma Aldrich, USA), a color reaction was achieved. Optical density was measured at 450 nm on an
ELISA plate-reader (iMark Microplate Absorbance Reader, Bio-Rad Laboratories, Austria).
2.4. Human Cardiomyocyte Culture and Immunoblot Analysis
Human cardiomyocytes (HCMs; Promo-Cell, Heidelberg, Germany) were cultivated in myocyte
growth medium supplemented with supplement mix (PromoCell), 1% L-glutamine 1% PenStrep in T75
flasks. For Western blot analysis, cells were seeded at a concentration of 2 × 105 cells in a 6-well plate.
In the case cells were not confluent, 3 mL of fresh cultivation medium was added. Twenty-four
hours later, the cultivation medium was replaced for basal medium for starvation medium
(supplemented only with 1% PenStrep and 1% L-glutamine) for 3 h. Then HCMs were treated
for 60 min with one of the three different conditioned media: PBMC ± 250 µL/mL ATG (pool
supernatant), PBMC ± 10 µg/mL anti-CD3 (pool supernatant), PBMC ± 10 µg/mL Isotype (pool
supernatant) or with Myocyte growth media.
Immunodetection was performed for the protein expression of the total and the phosphorylated
form of Akt and ERK 1/2 in HCMs by Western immunoblotting. 200 µL of RIPA buffer supplemented
with Phosphatase inhibitor were added to each well for the total protein isolation and quantified the
content of the extracts using Bradford assays. Proteins were then separated on Bolt 10% Bis-Tris Plus
Gel (Novex, Life Technologies, Carlsbad, CA, USA) and transferred onto nitrocellulose membranes.
Membranes were blocked for one h at room temperature (5% milk powder in TBS ± 0.1% Tween). The
following primary antibody (all from Cell Signaling Technology, Danvers, MA, USA) were used for
incubation overnight at 4 ◦C: Phospho-Akt (Ser473, 1:1000), Akt (pan) (C67E7, rabbit mAb, 1:1000),
Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204), rabbit mAb, 1:2000, p44/42 MAPK (Erk1/2) (137F5),
rabbit mAb, 1:1000.
This incubation was followed by the addition of the horseradish peroxidase (HRP) Envision±
labeled anti-mouse or anti-rabbit antibody (Dako, Santa Clara, CA, USA) diluted 1:500 in TBS-T ± 5%
Bovine Serum Albumin (BSA Sigma Aldrich, St.Louis, MO, USA). Band intensity from the membranes
was analyzed using the GE Healthcare Amersham™ ECL™ Prime Western Blotting Detection Reagent
1:1 (GE Healthcare Life Sciences, Chicago, Illinois, USA) and the ChemiDoc XRS imager (Bio-Rad,
Hercules, CA, USA) and measurements were repeated three times. Confirmation of equal loading was
done by the expression of α-actinin (1:1000, Santa Cruz Biotechnology, Dallas, TX, USA).
2.5. Human Umbilical Cord Endothelial Cell Assays
2.5.1. Tube Formation Assay
Twenty-four-well plates were coated with 300 µL Matrigel (Thermo Fisher Scientific, Waltham,
MA, USA) and incubated for one hour at 37 ◦C. Following this, 1× 105 human umbilical vein endothelial
cells (HUVEC, Thermo Fisher Scientific) were treated with one of the following secretomes or media:
PBMC plus 10 µg/mL CD3 (pooled supernatant), PBMC plus 10 µg/mL Isotype (pooled supernatant).
Medium 200 (Thermo Fisher Scientific) served as negative controls. The tube formation was visualized
and photographed using an inverted photomicroscope.
2.5.2. Scratch Migration Assay
For cell motility assay, the cultured human umbilical vein endothelial cells (HUVEC, Thermo
Fisher Scientific, Germany) were seeded at 4 × 104 cells/well into 2-well silicone inserts with a defined
cell-free gap, suitable for wound healing/migration assays (IBIDI, Gräfelfind, Germany). After 24 h of
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incubation at 37 ◦C with 5% CO2, the silicone insert was gently removed using a tweezers and the cells
were washed with Medium 200 supplemented with LVES (Thermo Fisher Scientific, Waltham, MA,
USA) to remove the un-adherent cells.
Subsequently, the cells were treated with different supernatants and media to evaluate their
impact on gap closure. The growth process over the gap was monitored at 0, 3, 6, 9, 12 and 24 h
by measuring cell confluence in a pre-defined, constant area including the gap using a Spark® 10M
multimode microplate reader (Tecan, Anif, Austria). The gap width was quantified using ImageJ
(v1.52i) software (National Institutes of Health, Bethesda, MD, USA).
2.6. Experimental Rat Model of Acute Myocardial Infarction
Animal experiments were approved by the Committee for Animal Research, Medical University
of Vienna 66.009/0122-WF/V/3b/2017. All experiments were performed in accordance with the Guide
for the Care and Use of Laboratory Animals by the National Institutes of Health (NIH Publication No.
85-23, revised 1996). Myocardial infarction was induced by ligation of the left coronary artery (LCA) as
described previously [27,28]. Briefly, male Sprague-Dawley rats were anesthetized by intraperitoneal
injection of mixture of Xylazine (4 mg/kg; Bayer, Germany) and Ketamine (100 mg/kg; Dr. E. Gräub AG,
Switzerland), intubated (14-gauge tube) and ventilated (9 mL/kg body weight, 75–85 stroke/min). Rats
allocated to (1) MI (n = 12 and (2) MI plus anti-CD3 group (n = 13) and were subjected to permanent left
coronary artery (LCA) ligation using 6-0 prolene. Rectal temperature was measured and maintained at
37.5–38.5 ◦C by a heated operating table. Myocardial ischemia was associated with cyanosis of the
myocardial area at risk and ST-elevation on the ECG signal. Analgesia was initiated by intraperitoneal
injection of Piritramide (0.1 mL/kg body weight) preoperatively and Piritramide in drinking water was
applied as a postoperative analgesic regimen (2 ampules of Piritramide with 30 mL of Glucose 5% in
250 mL water). Fifty micrograms of anti-CD3 antibodies suspended in 0.3 mL 0.9% saline solution was
injected into the femoral vein as a single dose. Injection of saline solution (vehicle) alone and sham
operation served as controls.
2.7. Histology
Rats were sacrificed six weeks after experimental infarction. Hearts were explanted and then
sliced at three layers at the level of the largest extension of infarcted area (n = 12 for 6 weeks analyses
in the control group, n = 13 in anti-CD3 antibody treatment). Slices were fixed in 10% neutral buffered
formalin and embedded in paraffin. The tissue samples were stained with hematoxylin-eosin (H&E)
and van Gieson (VG). Tissue samples were evaluated on an inverted microscope at 200× or 400×
magnification. Image J planimetry software (Rasband, W.S., Image J, U.S. National Institutes of Health,
Bethesda, USA) was utilized to determine the area of necrosis after three days and the size of myocardial
infarction after 6 weeks. Six weeks after induction of experimental AMI, a planimetric evaluation
was carried out on tissue specimens stained with VG for a better comparison of vital myocardium
and fibrotic areas. Infarction size was expressed as a percentage of the total left ventricular area as
previously described [29].
2.8. Flow Cytometry (FACS) Analysis
Extracellular vesicles (EVs) in the collected cell culture supernatant samples obtained after
stimulation with either 20 µg anti-CD3, 250 µg ATG antibodies, and untreated controls were stained
with antibodies against CD9, CD63, CD81 and HSP70 for analysis in flow cytometry.
For this, 75 µL microliters of supernatant were incubated for 15 min with labeled antibodies: 10
µL of CD81 FITC (BD Biosciences, Heidelberg, Germany), 1 µL of HSP70 PE (Abcam, Cambridge,
United Kingdom), 5 µL of CD63 PE-Cy7 (BD Biosciences), and 5 µL of CD9 APC (BD Biosciences), or
matching isotype controls (FITC, PE, and APC obtained from Life Technologies, Darmstadt, Germany;
PE-Cy7 obtained from BD Biosciences). In the next step, samples were then diluted with 400 µL
phosphate-buffered saline. To determine the number of the acquired events, size calibration beads
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were added to the samples (flow cytometry size calibration kit 1–15 µm from Life Technologies). The
samples were analyzed in a flow cytometer (FACS Calibur, BD Biosciences). MP was defined as
particles smaller than 1.5 µm and appropriately gated. MPs positive for the respective antibodies were
expressed as the percentage of events in the relevant gate. The obtained data were processed using
CellQuest Pro software (BD Biosciences).
2.9. ExoELISA CD81
Supernatants of ATG and anti-CD3 treated PBMCs were analyzed for concentrations of CD81
positive EVs using the commercially available ExoELISA CD81 kit (System Biosciences, Palo Alto, CA,
USA). In brief, EVs were captured on a protein binding microtiter plate precoated with an anti-CD81
primary antibody recognizing the tetraspanin protein on the exosomal surface. A Horseradish
Peroxidase enzyme-linked secondary antibody was used for signal amplification, before adding
a colorimetric TMB substrate solution. Color intensities were quantitated at 450 nm in an ELISA
plate-reader (iMark Microplate Absorbance Reader, Bio-Rad Laboratories, Austria).
2.10. Isolation of Total RNA and Preparation of Small RNA Libraries
EVs were purified by centrifugation at 100,000× g for 1.5 h at 4 ◦C. The pellet was lysed with 1000
µL Qiazol, supplemented with 1 µL of a synthetic RNA mixture containing three different synthetic
control RNAs (UniSp2, two fmol/mL; UniSp4, 0.02 fmol/mL; UniSp5, 0.0002 fmol/mL; Qiagen, Hilden,
Germany). RNA extraction was performed using 200 µL chloroform, and phase separation was achieved
by centrifugation for 15 min at 12,000× g at 4 ◦C. RNA was extracted from the upper aqueous phase
and purified on a QIAcube liquid handling robot using the miRNeasy Mini kit (Qiagen) with the
following modifications: glycogen (Ambion, Austin, TX, USA) was added to the aqueous phase to a final
concentration of 50 mg/mL and precipitated with 750 µL 100% ethanol. Columns were washed twice with
RPE buffer and RNA was eluted in a single round in 30 µL nuclease-free water and stored at –80 ◦C.
Small RNA Libraries were prepared from 2 µL RNA, using the CleanTag Small RNA Library Prep
Kit (TriLink Biotechnologies, San Diego, CA, USA) according to the manufacturer’s protocol. cDNA
libraries were amplified in 21 PCR cycles. Equimolar amounts were pooled and libraries underwent 50
cycles of single-end sequencing on a HighSeq 2500 (Illumina, San Diego, USA).
2.11. Nanoparticle Tracking Analysis (NTA)
Nanoparticle tracking analysis (NTA) was performed on purified PBMC-derived EV samples to
determine particle size and concentration using the ZetaView® PMX-120 instrument according to the
instructions of the manufacturer.
2.12. Next-Generation Sequencing Data Analysis
Raw reads were adapter trimmed using cutadapt, and quality checked using fastqc (v0.10.1).
Reads with sufficient length (> 18 nt) and quality (phred > 30) were sequentially mapped against all
human mature microRNA sequences (miRBase v20) and the human genome (GRCh37). MicroRNA
reads were normalized to the total library size to yield reads per million (RPM) for visual representation.
Raw read counts were subsequently used in EdgeR to identify microRNAs differentially expressed in
extracellular vesicles derived from anti-CD3 versus Isotype control-treated PMBCs, applying modified
paired t-tests [30]. Principal component analysis and hierarchical clustering were performed using
miRNA RPM values and clustvis (https://biit.cs.ut.ee/clustvis/).
2.13. Statistical Analysis
Statistical analysis was performed using GraphPad Prism software (GraphPad Prism version 8.00 for
Windows, GraphPad Software, San Diego California USA, www.graphpad.com”). All data are given
as mean ± SEM. The repeated ANOVA and one-way analysis of variance or Kruksal-Wallis test were
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utilized accordingly to calculate significances between the groups. The Dunnett’s and the Dunn’s multiple
comparison post-tests were utilized, and the Benjamini-Hochbergs method for false-discovery rate (FDR)
to adjust for multiple testing was applied as appropriately. Generally, p-values < 0.05 were considered
statistically significant (p-values were expressed as follows: * p < 0.05, ** p < 0.01, *** p < 0.001).
3. Results
3.1. Cell Culture Supernatants Obtained from PBMCs Co-Incubated with ATG and Anti-CD3 Antibody Show
High Concentrations of Chemokines
Cell cultures of human PBMCs were supplemented with different doses of ATG or various anti-T-cell
antibodies, such as treatment with anti- (1) IgG2a, (2) IgG1, (3) CD4, (4) CD8, (5) CD11a, (6) CD3, (7)
CD28, (8) CD2, (9) HLA-DR. After 24 h incubation, supernatants were collected and the concentration of
IL-8 and MCP-1 was assessed by ELISA. Compared to ATG (4005 ± 1378 pg/mL), only the addition of
anti-CD3 antibodies led to significantly increased IL-8 expression (21438 ± 14990 pg/mL; p < 0.001 vs.
ATG; Figure 1a), whereas the addition of anti-IgG2a (531 ± 193 pg/mL; p = n.s.), anti-IgG1 (22231 ± 666
pg/mL p = n.s.), anti-CD4 (1327 ± 140 pg/mL; p = n.s.), anti-CD8 (1298 ± 181 pg/mL; p = n.s.), anti-CD11a
(751 ± 104 pg/mL; p = n.s.), anti-CD28 (3062 ± 2673 pg/mL; p = n.s.), anti-HLA-DR (2375 ± 263 pg/mL; p
= n.s.) did not lead to higher IL-8 concentrations in the PBMC supernatant. Similarly, the incubation with
anti-CD3 (41835 ± 10241 pg/mL; p < 0.01) led to increased MCP-1 concentrations in the PBMC supernatant,
which were markedly higher compared to ATG (19399 ± 9078 pg/mL). In contrast, all other antibodies
did not lead to appreciable increases in MCP-1 levels. For proof of concept of previous work showing
an increased secretion of chemokines after ATG-stimulation in PBMCs, PBMCs were co-incubated with
ATG versus control and concentrations of chemokines in supernatants were quantified using an array.
Concentrations of several chemokines, including IL-8, showed marked alterations upon treatment of
PBMCs with ATG (Supplemental Figure S1).
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were expressed as follows: ** p < 0.01, *** p < 0.001).
3.2. Effects of Systemic Intravenous Anti-CD3 Treatment on Myocardial Scar Size
As described above, experimental myocardial infarction was evaluated in a rat model, subjected
to left coronary artery ligation. Six weeks after the induction of acute myocardial infarction and
subsequent anti-CD3 treatment, hearts were explanted, and myocardial scar size was determined.
The hearts obtained from rats treated with anti-CD3 antibodies evidenced smaller scar formation.
Accordingly, a planimetric analysis showed a scar size of 27.8% (IQR 16.2-34.9) of the left ventricle in
control animals, while this was significantly reduced to 12.6% in the specific treatment group (IQR
8.3-27.2, p < 0.01, n = 12–13 per group, Figure 2a, representative pictures in Figure 2b).
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Figure 2. Rats were subjected to permanent left coronary artery (LCA) ligation. Rats were sacrificed 6
weeks after experimental infarction. Hearts were explanted and then sliced at three layers at the level of
the largest extension of infarcted area and infarct sizes compared after staining with hematoxylin-eosin
(H&E) and van Gieson (VG). (a) In animals treated with anti-CD-3 antibody (n = 13) left ventricular scar
size was significantly reduced [12.6% (IQR 8.3–27.2) vs. 27.8% (IQR 16.2–34.9) p < 0.01] compared to
vehicle treatment (n = 12). Representative (b) pictures are shown. (p-values were expressed as follows:
** p < 0.01).
3.3. Induction of Chemotaxis and Angiogenesis by the Secretomes of Anti-CD3 Treated PBMC
The effects of exposure of HUVECs to secretomes of PBMC after anti-CD3 treatment were evaluated
in both a scratch assay for studying cell migration and in a tube assay for the assessment of promotion
or inhibition of tube formation as a surrogate parameter of angiogenesis. Compared to isotype control
(100%), exposure to PBMC supernatant after anti-CD3 antibody (94 ± 2%; p = n.s. versus isotype
control), medium alone (108 ± 1%; p = n.s. versus isotype control) and medium ± RPMI (98 ± 2%;
p = n.s. versus isotype control) did not induce tube formation (Figure 3a). Similarly, gap closure in
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HUVECs was not increased by coincubation with PBMC supernatant after anti-CD3 antibody treatment
(90 ± 1%; p = n.s.) compared to an isotype control (84 ± 2%) and medium alone (98 ± 1%; p = n.s.;
Figure 3b). Furthermore, exposure to PBMC supernatant after anti-CD3 antibody treatment did not
increase angiogenin secretion in HUVECs compared to an isotype control (800 ± 200 pg/mL versus 852
± 105 pg/mL, p = n.s.).
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Figure 3. human umbilical vein endothelial cell (HUVECs) were exposed to anti-CD3 treated PBMCs.
Cell migration and angiogenesis were assessed by (a) tube assay and (b) tube formation, respectively.
Compared to isotype control (100%), exposure to supernatant of anti-CD3 treated PBMC did not induce
(a) endothelial cell tube formation (94 ± 2%; p = n.s. versus isotype control) (b) nor chemotaxis (90 ±
1%; p = n.s.) in HUVECs.
3.4. Effects of Exposure to Anti-CD3 Treated PBMC Supernatant on Intracellular Pathways in Human
Cardiomyocytes
The effect of anti CD3 treatment on intracellular pathways was investigated by Western
Immunoblotting. Treatment with PBMC supernatant after anti-CD3 antibody treatment did not
alter phosphorylation of ERK1/2 (0.30 ± 0.17 versus 0.46 ± 0.13 protein expression/alpha-actinin; p =
n.s) and Akt (0.05 ± 0.01 versus 0.08 ± 0.02 protein expression/alpha-actinin; p = n.s.; all p-values versus
CD3) compared to isotype control in human cardiomyocytes, or compared to ATG (p-ERK1/2 0.52 ±
0.39 protein expression/alpha-actinin; p = n.s.; p-Akt 0.10 ± 0.01 protein expression/alpha-actinin; p =
n.s.; all p-values versus CD3) or medium (ERK1/2 1.16 ± 0.18 protein expression/alpha-actinin; pAkt
0.10 ± 0.04; p = n.s.; all p-values versus CD3) treatment (Figure 4).
3.5. FACS Analysis of Exosomes Markers on EVs of PBMC after Incubation with Anti-CD3 Antibodies
Using exoELISA, we assessed the concentration of CD81 positive exosomes: There were no
quantitative changes in the numbers of exosomes positive for the exosome marker CD81 (20.94 ± 4.84
× 106 exosomes/µL versus 39.36 ± 3.14 × 106 exosomes/µL; p = n.s.; Figure 5a), indicating that the
quantitative EV secretion in PBMCs is not affected by anti-CD3 antibodies.
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Figure 4. The effect of anti-CD3 treat ent on intracellular path ays as investigated by estern
I unoblotting. In human cardiomyocytes, co-incubation with supernatant of PBMCs treated
with anti-CD3 antibody did not alter phosphorylation of Akt (0.05 ± 0.01 versus 0.08 ± 0.02
protein expression/alpha-actinin; p = n.s.) and ERK1/2(0.30 ± 0.17 versus 0.46 ± 0.13 protein
expression/alpha-actinin; p = n.s) compared to isotype control. Representative pictures of the isotype
(1), ATG (2), anti-CD3 (3) and medium plus FCS (4) conditions are shown.
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These findings were also confirmed by FACS analysis for the assessment of EV markers (HSP70,
CD9, CD63 and CD81) on EVs of cultured PBMC after co-incubation with anti-CD3 antibodies
(Figure 5b). The expression of exosomes positive for CD9 (74 ± 4% versus 75 ± 2%; p = n.s), HSP70 (22
± 8% versus 23 ± 8%; p = n.s) or CD81 (11 ± 3% versus 12 ± 4%; p = n.s.) was unchanged, while a slight,
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but not significant increase in CD63+ exosomes (14 ± 1% versus 17 ± 2; p = n.s.) was detected upon
anti-CD3 antibody treatment compared to isotype control. Concomitantly, using NTA, no differences
in extracellular vesicle size and concentration were detected (data not shown).
3.6. miRNA Screening in EVs and Alterations in miRNA Signaling Caused by Anti-CD3 Stimulation
Despite EV numbers being unaffected by anti-CD3 antibody treatment, they may still contain
different contents, including miRNAs. This finding prompted us to analyze miRNA contents by
next-generation sequencing. Three hundred twenty-two miRNAs were detected across all samples
at a sufficient level (RPM > 5) and considered for statistical analysis. Out of these, 32 miRNAs
(10%) showed a significant change upon anti-CD3 stimulation (Table 1 and Figure 6). These include
miRNAs miR-19a-3p and miR-19b-3p, miR-26b-5p, miR-30e-5p, miR125a-5p, miR-181d-5p, miR-186-5p,
miR-301a-3p and miR-335-5p, which have been described as relevant in cardiovascular context (see
Discussion). Thus, our findings will also provide the basis for the more detailed analysis of putatively
relevant miRNA candidates.
Table 1. In total, 32 of 322 miRNAs showed a significant change upon anti-CD3 stimulation in
next-generation sequencing. Raw read counts were used in EdgeR to identify microRNAs differentially
expressed in extracellular vesicles derived from PBMCs treated with anti-CD3 versus Isotype control.
miRNA logFC p-value
hsa-miR-19a-3p 1.01 0.001
hsa-miR-374a-5p 1.46 0.003
hsa-let-7a-3p 0.50 0.004
hsa-miR-6842-3p 1.12 0.005
hsa-miR-301a-3p 1.09 0.007
hsa-miR-664a-3p 1.12 0.011
hsa-miR-181d-5p 0.57 0.011
hsa-miR-30e-5p 0.51 0.011
hsa-miR-151a-3p 0.48 0.012
hsa-miR-19b-3p 0.83 0.013
hsa-miR-1277-5p 2.23 0.015
hsa-miR-374a-3p 0.60 0.016
hsa-miR-548e-5p 1.56 0.016
hsa-miR-32-3p 1.44 0.017
hsa-miR-186-5p 1.12 0.019
hsa-miR-221-3p 0.68 0.019
hsa-miR-548k 1.71 0.022
hsa-miR-335-5p 1.62 0.026
hsa-miR-134-5p 1.27 0.027
hsa-miR-26b-5p 0.61 0.027
hsa-miR-1273h-3p 0.79 0.029
hsa-miR-425-5p 0.91 0.030
hsa-miR-766-5p 1.00 0.032
hsa-miR-125a-5p 1.53 0.037
hsa-miR-152-3p 0.87 0.037
hsa-miR-361-5p 0.70 0.037
hsa-miR-33a-5p 1.09 0.040
hsa-miR-181c-5p 0.67 0.043
hsa-miR-197-3p 0.61 0.043
hsa-miR-7-5p 0.72 0.043
hsa-miR-543 1.37 0.044
hsa-miR-625-5p 0.79 0.044
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including miRNAs miR-19a-3p and miR-19b-3p, miR-26b-5p, miR-30e-5p, miR125a-5p, miR-181d-5p,
miR-186-5p, miR-301a-3p and miR-335-5p.
4. Discussion
In this study, (1) sy temic intravenous treatment it tibody markedly reduced
scar formation i a rat model of AMI, (2) exposure to PB t t after anti-CD3 antibody
treatment did neither induce cardioprotective pathways in huma cardiomyocytes, nor pro-angiogenetic
mechanisms in vitro in HUVECs and (3) PBMC incubation with a anti-CD3 antibody led to a qualitative
but not quantitative change of the exosome and miRNA expression.
Ischemic cardiomyopathy due to acute myocardial infarction (AMI) constitutes a challenge to
patients and health systems [1]. The initial hope that stem cell therapy has a benefit was disappointed
by several large clinical trials. [2–5]. Consequently, the so-called “paracrine paradigm” was formulated
stating not the stem cells themselves but their secretomes are responsible for some of the promising
results in clinical trials investigating “stem cell” therapy [10,11]. Several mechanisms including infusion
of apoptotic cell suspensions after irradiation, were shown to be cardioprotective and reduce infarct
size, underscoring the theoretical merit of the “paracrine paradigm” [31–33]. The “stem cells” likely
mediated the observed effects through their secretomes and not via cellular incorporation and direct
tissue regeneration [34]. Therefore, the infusion of “stem cells” per se might be unnecessary [35].
Whereas treatment with ATG was shown to decrease infarct size in a preclinical model of AMI in
rats, using ATG in a clinical setting in patients with AMI is prohibited due to several side-effects. We,
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therefore, investigated a way of inducing a similar “danger signal” in PBMC through T-cell stimulation
mediated through only one epitope. Using an array, we first confirmed IL-8 as a potent surrogate
parameter for ATG-induced secretory changes in PBMC. We are aware that in the stem cell trials,
bone-marrow-derived stem cells (BMSC) were used as opposed to PBMC and that Wollert et al. showed
distinct expression patterns of PBMC and BMSC [13,14]. However, firstly, in our previous work, PBMC
and BMSC were comparable regarding IL-8 secretion. Secondly, we think that although the concept
of antibody treatment for cardioprotection originates from “stem cell therapy”, it now transcends
this idea. PBMC were, therefore, chosen to assess this question as PBMC are comparable to stem
cells with regards to exosome secretion but easier to obtain and more cost-efficient and abundant in
whole blood and therefore pass the coronaries constantly, where they might work as “bioreactors” of
cardioprotective factors [14].
Compared to ATG, CD3-mediated stimulation resulted in a more profound IL-8 and MCP-1
expression pattern, an established surrogate marker of changes in exosome secretion. We, therefore,
concluded that specific anti-CD3 antibody treatment could theoretically combine the efficacy of ATG
treatment with better safety. Of note, while an effective reduction of left ventricular scar size in an
animal AMI model compared to control could be observed, the issue of safety of anti-CD3 treatment
in humans suffering from AMI is beyond the scope of this study. It is noteworthy that the safety of
anti-CD3 antibody treatment has been proved in a recent trial [26].
At least partly, the beneficial effects observed in our animal model of AMI might be mediated
through IL-8 and cytokines. We and others showed previously that cell-free suspension of PBMC
evidencing high IL-8 induced angiogenesis and cardioprotective pathways [13]. However, in this
study, PBMC supernatant after anti-CD3 antibody treatment did not induce increased migration
and tube formation in HUVECs. Further, angiogenin secretion was not increased in HUVEC
co-incubated with supernatant of PBMCs treated with an anti-CD3 antibody. Contrary to our
expectation, exposure to PBMC supernatant after anti-CD3 antibody treatment did not significantly
induce known cardioprotective signaling pathways such as phosphorylation of Akt and Erk1/2 in
human cardiomyocytes. Therefore, the observed effects of anti-CD3 antibody treatment in our AMI
model are likely not predominantly due to classical primarily cardioprotective mechanisms but
influenced by changes in other mechanisms resulting in the observed cardioprotective phenotype. In
a previous study, p53, a known mediator of cardioprotection, was downregulated in a rat model of
AMI after ATG treatment [7]. However, in this study, ATG also triggered the release of cytokines as
well as neoangiogenesis and chemotaxis, which we could not detect in our study evaluating specific
anti-CD3 treatment. We, therefore, think that ATG treatment does not only differ with regards to
the applicability to anti-CD3 treatment, but also regarding the mechanistic pathways by which the
observed cardioprotective phenotypes were mediated. Therefore, furthermore, both quantitative and
qualitative changes in exosomes, which are known to have cardioprotective capabilities, were assessed
in this study [23]. Indeed, pronounced effects on several distinct miRNAs were observed.
Several miRNA were significantly upregulated in the anti-CD3 treated PBMC supernatant. The
assessment of their specific roles on the cardioprotective effect observed in this study are beyond the
scope of this manuscript. The effects of miRNA in heart disease and cardio-protection are reviewed
elsewhere [35–38].
Different miRNAs could contribute to this effect. miR-19 was shown to induce tissue factor
in breast cancer cells [39]. Recently, Li et al. described the miR-19 family as a potential target in
cardiovascular medicine [40]. miR-19 and miR-186 were evaluated in the context of coronary heart
disease and the diagnosis of acute myocardial infarction [41]. miR-134 was shown to be a potential
biomarker for both AMI and adverse outcome including the development of heart failure after AMI [42].
miR-26 plasma concentration was shown to be associated with AMI [43]. miR-374 was shown to be
pro-hypertrophic and to be involved in VEGF-receptor-1 signaling [44]. The miR-26 family plays
an essential role in angiogenesis, epithelial cell growth and tissue repair [45]. miR-30 was shown to
be cardioprotective in heart failure inhibiting cardiomyocyte autophagy [46]. The miR-30 family is
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abundant in the heart and to participate in ventricular remodeling through autophagy, inflammatory
pathways and apoptotic mechanisms [47]. miR-146a is known to be cardioprotective and to reduce
infarct size in in vivo animal models of AMI [48]. miR-186 was shown to play a crucial role in vascular
endothelial cell angiogenesis [49]. miR-221 was shown to inhibit autophagy after hypoxia and was
postulated to be a possible target in treating ischemia-reperfusion injury [50].
The physiologic and pathophysiologic changes induced by distinct miRNA expression patterns
and the clinical relevance of these miRNA alterations are beyond the scope of this manuscript. However,
we speculate that the observed cardioprotective effect of anti-CD3 treatment in vivo could potentially
result from alterations in miRNA expression and concentration. We provide new data for future studies
evaluating miRNA alterations in the setting of cardioprotective treatment.
Limitations
Several limitations need to be addressed. Firstly, we lack functional in vivo data such as cardiac
magnetic resonance imaging and pressure measurements. Secondly, we do not have a proof for
actual T-cell stimulation by the anti-CD3 in vivo treatment, though there seems to be cross-species
reactivity when administrating human ATG antibodies in rats as an increase of the IL-8 analog CXCL1
was found in rats [1]. Of note, human and rat anti-CD3 antibodies were used in vitro and in vivo
respectively in this study. Thirdly, the data about the physiological relevance of the qualitative change
of the exosome expression pattern remains speculative and therefore thesis-generating. Fourthly, as
discussed above, although Akt and Erk represent critical pathways, other cardioprotective extracellular
and intracellular pathways that were not specifically evaluated in this study could also contribute to
the observed phenotype. Penultimately, the in-vivo AMI model evaluating the effects of anti-CD3
antibody lacks a true randomization as well as a baseline measure of initial myocardial injury size
in the anti-CD3 versus control group. Of note, however, the analysis of the infarct sizes was blinded.
Finally, this study lacks data on the interplay between T-cells and other cells of the immune system
such as macrophages which were reported to play a role in exogenous cell therapy but also remodeling
after AMI [51,52]. To conclude, we consider this manuscript to be hypothesis-generating: Treatment
with an anti-CD3 antibody led to decreased scar size in a rat model of AMI, however, not due to (1)
induction of angiogenesis, (2) classical cardioprotective pathways and (3) quantitative changes in
exosomes. We, therefore, conclude that subtle qualitative changes in the miRNA expression could
contribute to this exploratory finding. Further studies are warranted to evaluate the thesis-generating
results reported in this manuscript.
5. Conclusions
Treatment with an anti-CD3 antibody led to decreased scar size in a rat model of AMI. Whereas
cardioprotective and pro-angiogenetic pathways were unaltered by anti-CD3 treatment, qualitative
changes in the EVs miRNA expression could be observed, which might be causal for the observed
cardioprotective phenotype. We provide evidence that EVs are a potential cardioprotective treatment
target. Our findings will also provide the basis for a more detailed analysis of putatively relevant
miRNA candidates.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4409/9/2/295/s1,
Figure S1: Concentrations of several chemokines, including IL-8, showed marked alterations upon treatment of
PBMCs with ATG.
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